We are committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs for the treatment of infectious diseases. The Company's programs include drug candidates for the prevention of catheter-related infections (Phase III); The treatment of dermatological diseases (end of Phase II), serious gram positive bacterial infections (preclinical) and hepatitis B infections (preclinical).

• News Releases:
• Sept. 1, 2010 (PDF)
  BIOWEST THERAPEUTICS announces resignation of CEO and Director.
• July 30, 2010 (PDF)
  BIOWEST THERAPEUTICS reports fiscal 2010 financial results.
• June 29, 2010 (PDF)
  BIOWEST THERAPEUTICS announces appointment of new chief financial officer.